Last updated on April 24, 2014 at 1:21 EDT

Medicago to Present at the 24th Annual Roth Growth Stock Conference

March 9, 2012

QUEBEC CITY, QC, March 9, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG), a
biopharmaceutical company focused on developing highly effective and
competitive vaccines based on proprietary manufacturing technologies
and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon,
President and Chief Executive Officer of Medicago, will be presenting
at the 24(th) Annual Roth Growth Stock Conference. The conference is being held March
11-14, 2012 at the Ritz Carlton Laguna Niguel in Dana Point,
California. Mr. Sheldon is scheduled to present on March 13(th), 2012 at 10:30 a.m. Pacific Time.

About the Roth Growth Stock Conference
The Roth Growth Stock Conference brings together executives from over
400 growth companies, one of the largest of its kind in the US. This
event is designed to provide investors with a unique opportunity to
gain insight into small and mid-cap growth companies across a variety
of sectors, including energy, software, technology, industrials,
healthcare, media, consumer and retail.

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements
This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from current
expectations, including the matters discussed under “Risks Factors and
Uncertainties” in Medicago’s Annual Information Form filed on March 31,
2011 with the regulatory authorities. Medicago assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward-looking

SOURCE Medicago Inc.

Source: PR Newswire